Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts
Peanut Allergy Therapy Has Been Commercial Flop
Executive Summary
Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.
You may also be interested in...
Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss
Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.
First Wave Rises With Sanofi GI Deal
First Wave is licensing Sanofi’s 5-HT4 receptor partial agonist capeserod and is having to pay a mere $500,000 in upfront fees for the privilege.